{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T15:59:12Z","timestamp":1698422352974},"reference-count":18,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.3892\/br.2014.360","type":"journal-article","created":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T06:01:59Z","timestamp":1410328919000},"page":"915-917","source":"Crossref","is-referenced-by-count":2,"title":["Cathepsin K in treatment monitoring following intravenous zoledronic acid"],"prefix":"10.3892","volume":"2","author":[{"given":"OLIVER","family":"JAHN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"THOMAS","family":"WEX","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SILKE","family":"KLOSE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SIEGFRIED","family":"KROPF","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DANIELA","family":"ADOLF","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"STEFAN","family":"PIATEK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,9,10]]},"reference":[{"key":"key20180107141953_b1-br-02-06-0915","first-page":"S1","article-title":"Consensus Development Conference on Osteoporosis. Hong Kong, April 1\u20132, 1993","volume":"95","year":"1993","journal-title":"Am J Med"},{"key":"key20180107141953_b2-br-02-06-0915","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group","volume":"843","year":"1994","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"Suppl 6","key":"key20180107141953_b3-br-02-06-0915","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/s001980070007","article-title":"Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"issue":"Suppl 6","key":"key20180107141953_b4-br-02-06-0915","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/s001980070002","article-title":"The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"key":"key20180107141953_b5-br-02-06-0915","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S8756-3282(00)00271-4","article-title":"Monitoring individual response to hormone replacement therapy with bone markers","volume":"26","author":"Delmas","year":"2000","journal-title":"Bone"},{"key":"key20180107141953_b6-br-02-06-0915","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0889-8529(02)00077-4","article-title":"Biochemical markers of bone remodeling","volume":"32","author":"Seibel","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"key20180107141953_b7-br-02-06-0915","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.clinbiochem.2012.01.022","article-title":"The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis","volume":"45","author":"Szulc","year":"2012","journal-title":"Clin Biochem"},{"key":"key20180107141953_b8-br-02-06-0915","first-page":"52","article-title":"The epidemiology of osteoporosis - Bone Evaluation Study (BEST): an analysis of routine health insurance data","volume":"110","author":"Hadji","year":"2013","journal-title":"Dtsch Arztebl Int"},{"key":"key20180107141953_b9-br-02-06-0915","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1358\/dnp.2004.17.1.829022","article-title":"The role of cathepsin K in normal bone resorption","volume":"17","author":"Troen","year":"2004","journal-title":"Drug News Perspect"},{"key":"key20180107141953_b10-br-02-06-0915","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/bbrc.1995.1013","article-title":"Molecular cloning of human cDNA for cathepsin K: novel cystein protease predominantly expressed in bone","volume":"206","author":"Inaoka","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107141953_b11-br-02-06-0915","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","article-title":"Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency","volume":"273","author":"Gelb","year":"1996","journal-title":"Science"},{"key":"key20180107141953_b12-br-02-06-0915","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","article-title":"Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice","volume":"95","author":"Saftig","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107141953_b13-br-02-06-0915","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00198-006-0286-8","article-title":"Assessment of osteoclast number and function: application in the development of new and impoved treatment modalities for bone diseases","volume":"18","author":"Henriksen","year":"2007","journal-title":"Osteoporos Int"},{"key":"key20180107141953_b14-br-02-06-0915","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1055\/s-0037-1619912","article-title":"DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen","volume":"18","year":"2009","journal-title":"Osteologie"},{"key":"key20180107141953_b15-br-02-06-0915","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.maturitas.2011.11.024","article-title":"Serum cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women","volume":"71","author":"Adolf","year":"2012","journal-title":"Maturitas"},{"key":"key20180107141953_b16-br-02-06-0915","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.lab.2005.03.016","article-title":"Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures?","volume":"146","author":"Holzer","year":"2005","journal-title":"J Lab Clin Med"},{"key":"key20180107141953_b17-br-02-06-0915","first-page":"1","article-title":"Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget\u2019s disease","volume":"52","author":"Meier","year":"2006","journal-title":"Clin Lab"},{"key":"key20180107141953_b18-br-02-06-0915","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.maturitas.2009.09.011","article-title":"Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate","volume":"64","author":"Munoz-Torres","year":"2009","journal-title":"Maturitas"}],"container-title":["Biomedical Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/br.2014.360\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T17:15:02Z","timestamp":1565802902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/br.2014.360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,10]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,9,10]]},"published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.3892\/br.2014.360"],"URL":"https:\/\/doi.org\/10.3892\/br.2014.360","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,10]]}}}